美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kardigan

22.00

+6.0037.50%

盤後：22.000.00000.00%19:59 EDT

成交量：584.44萬

成交額：1.14億

市值：19.29億

市盈率：-8.39

高：23.75

開：16.25

低：16.25

收：16.00

52周最高：23.75

52周最低：16.25

股本：8,767.25萬

流通股本：2,333.33萬

量比：- -

換手率：25.05%

股息：- -

股息率：- -

每股收益(TTM):-2.6230

淨資產收益率：--

總資產收益率：--

市淨率：-6.42

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Kardigan

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.kardigan.bio

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Kardigan, Inc.於2023年8月根據特拉華州法律註冊成立。該公司是一家臨床階段的精準治療公司，致力於開發針對特定心血管疾病根本病因的藥物，這些疾病目前尚無獲批療法。公司的使命是并行開發多種靶向心血管療法，使心血管疾病患者早日獲得應有的治癒。公司目前有三個處於後期臨床開發階段的項目：Danicamtiv、Ataciguat和Tonlamarsen，這些項目針對的適應症目前尚無獲批療法。管理團隊擁有深厚的心血管疾病領域知識，並運用創新的藥物開發方法，結合公司專有的 Prolaio 平台的數據和分析技術，以高效執行的方式快速交付成果。公司在心血管藥物開發中秉持高度精準的理念，着眼於疾病的根本原因，而非後期出現的心血管癥狀。

董事

名稱

職位

Tassos Gianakakos

Chair and Chief Executive Officer and Director

David Meeker

Director

Douglas Giordano

Director

Kim Popovits

Director

Paul Berns

Director

Tim Walbert

Director

股東

名稱

職位

Tassos Gianakakos

Chair and Chief Executive Officer and Director

Brianne Puglisi

Chief Financial Officer

Andy Pasternak

Chief Strategy Officer

Jay Edelberg

Chief Medical Officer

John B. Moriarty, Jr.

Chief Legal Officer and Corporate Secretary

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KARD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KARD\",,,,,undefined,":{"symbol":"KARD","market":"US","secType":"STK","nameCN":"Kardigan","latestPrice":22,"timestamp":1781812800000,"preClose":16,"halted":0,"volume":5844442,"hourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:59 EDT","volume":49387,"amount":1039648.3023,"timestamp":1781827198381,"change":0,"changeRate":0,"amplitude":0.086818},"delay":0,"changeRate":0.375,"floatShares":23333300,"shares":87672455,"eps":-2.623,"marketStatus":"休市中","change":6,"latestTime":"06-18 16:00:00 EDT","open":16.25,"high":23.75,"low":16.25,"amount":113636875.58236,"amplitude":0.46875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.623,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1781755200000,"exchange":"NASDAQ","adjPreClose":16,"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:59 EDT","volume":49387,"amount":1039648.3023,"timestamp":1781827198381,"change":0,"changeRate":0,"amplitude":0.086818},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KARD\",,,,,undefined,":{"symbol":"KARD","floatShares":23333300,"roa":"--","roe":"--","lyrEps":0,"shares":87672455,"dividePrice":0,"high":23.75,"amplitude":0.46875,"preClose":16,"low":16.25,"week52Low":16.25,"pbRate":"-6.42","week52High":23.75,"institutionHeld":0,"latestPrice":22,"eps":-2.623,"divideRate":0,"volume":5844442,"delay":0,"ttmEps":-2.623,"open":16.25,"prevYearClose":16,"prevWeekClose":16,"prevMonthClose":16,"prevQuarterClose":16,"fiveDayClose":16,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KARD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.kardigan.bio","stockEarnings":[{"period":"1week","weight":0.375},{"period":"ytd","weight":0.375}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Kardigan, Inc.於2023年8月根據特拉華州法律註冊成立。該公司是一家臨床階段的精準治療公司，致力於開發針對特定心血管疾病根本病因的藥物，這些疾病目前尚無獲批療法。公司的使命是并行開發多種靶向心血管療法，使心血管疾病患者早日獲得應有的治癒。公司目前有三個處於後期臨床開發階段的項目：Danicamtiv、Ataciguat和Tonlamarsen，這些項目針對的適應症目前尚無獲批療法。管理團隊擁有深厚的心血管疾病領域知識，並運用創新的藥物開發方法，結合公司專有的 Prolaio 平台的數據和分析技術，以高效執行的方式快速交付成果。公司在心血管藥物開發中秉持高度精準的理念，着眼於疾病的根本原因，而非後期出現的心血管癥狀。","exchange":"NASDAQ","name":"Kardigan","nameEN":"Kardigan"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KARD\",market:\"US\",,,undefined,":{"directors":[{"name":"Tassos Gianakakos","position":"Chair and Chief Executive Officer and Director"},{"name":"David Meeker","position":"Director"},{"name":"Douglas Giordano","position":"Director"},{"name":"Kim Popovits","position":"Director"},{"name":"Paul Berns","position":"Director"},{"name":"Tim Walbert","position":"Director"}],"executives":[{"name":"Tassos Gianakakos","position":"Chair and Chief Executive Officer and Director"},{"name":"Brianne Puglisi","position":"Chief Financial Officer"},{"name":"Andy Pasternak","position":"Chief Strategy Officer"},{"name":"Jay Edelberg","position":"Chief Medical Officer"},{"name":"John B. Moriarty, Jr.","position":"Chief Legal Officer and Corporate Secretary"}]}}}